Want to join the conversation?
$PRGO 3Q15 10-Q: 3Q15-end total assets were $16.1Bil, down 1.8% sequentially and total liabilities were $6.5Bil, down 2.9% sequentially. PRGO and Biogen will each be responsible for 50% of losses and expenses arising out of any Tysabri® product liability claims.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.